Cipla News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Cipla Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 5
Author: ICICI Securities Limited

Keep track of all breaking news and updates on Cipla from all sources in a single place.

Cipla Ltd.

12 May 2026, 02:08PM

1292.30

-0.97%

Cipla Q4 preview: Profit may plunge on weak US sales; check estimates here

Business Standard

Cipla's March 2026 quarter revenue is expected to decline marginally to 6,665 crore as compared to 6,730 crore in the year-ago period

Cipla Ltd. has an average target of 1598.89 from 9 brokers.

Cipla Ltd.

06 May 2026

1292.30

-0.97%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper publication under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

pdf

Cipla Ltd.

27 Apr 2026

1292.30

-0.97%

Cohance Lifesciences shares zoom 20% to hit upper circuit; here's why

Business Standard

Cohance Lifesciences share price today: Cohance Lifesciences, a contract development and manufacturing organisation, has appointed Cipla's ex-CEO Umang Vohra as its executive chairman and group CEO.

Cipla Ltd. has an average target of 1598.89 from 9 brokers.

Cohance Lifesciences appoints former Cipla chief Umang Vohra as Executive Chairman, Group CEO

Business Line | 27 Apr 2026

Cipla Ltd.

24 Apr 2026

1292.30

-0.97%

Cipla gains US FDA nod for gVentolin; analysts see $100 mn sales potential

Business Standard

Cipla has received the US FDA's approval for generic Ventolin inhaler. Analysts see $100-million sales potential from the drug, which could aid US business outlook

Number of FII/FPI investors decreased from 1052 to 964 in Mar 2026 qtr

Cipla Ltd.

24 Apr 2026

1292.30

-0.97%

Launches to address concern on US growth; valuation attractive

Buy: Cipla Ltd.

Target

ICICI Securities Limited

Cipla’s recent product approval of gOfev and gVentolin from the USFDA is likely to start allaying concerns arising on its US growth post the discontinuation of Lanreotide, loss of exclusivity in gRevlimid and regulatory issues at key plants in India.

ICICI Securities Limited decreased Buy price target of Cipla Ltd. to 1550.0 on 24 Apr, 2026.

Cipla Ltd.

23 Apr 2026

1292.30

-0.97%

Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosol

Business Line

The final approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Albuterol sulfate inhalation aerosol of strength 90 mcg per actuation

Number of FII/FPI investors decreased from 1052 to 964 in Mar 2026 qtr

Cipla gets USFDA nod for respiratory issues treatment inhalation aerosol

Business Standard | 23 Apr 2026

Cipla Ltd.

23 Apr 2026

1292.30

-0.97%

Company Update

Cipla Ltd - 500087 - Cipla Receives U.S. FDA Approval For First AB Rated Generic Of …

BSE India

Please find enclosed intimation

pdf

Cipla Ltd.

23 Apr 2026

1292.30

-0.97%

Cipla gets USFDA nod for albuterol inhaler, strengthening US respiratory play

Neutral: Cipla Ltd.

Target

Motilal Oswal

Cipla received USFDA approval for the first AB-rated generic of Ventolin HFA (albuterol inhaler), giving it a first-to-market edge with pharmacy-level substitution in the US.